Latest Breaking News On - Francesca barone - Page 1 : comparemela.com

Chief Science Officer Talks Innovation In Cancer Research

Francesca Barone, CSO of Candel Therapeutics CADL, was recently interviewed by Benzinga. Candel is a clinical-stage biopharmaceutical company focused on…

Francesca baroneCandel therapeuticsReaking news

Micro-Cap Cancer Focused Candel Therapeutics Highlights Encouraging Data From Brain Tumor Immunotherapy - Candel Therapeutics (NASDAQ:CADL)

Data from Candel Therapeutics on CAN-3110, a promising viral immunotherapy for recurrent high-grade glioma. Discover survival rates and potential advancements in cancer treatment.

Francesca baroneCandel therapeuticsChief scientific officer

Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma

Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesTheodore jenkinsFrancesca baroneAljanae reynoldsExchange commissionDrug administrationBusiness developmentGlioblastoma drug development summitCompany nasdaqCandel therapeutics incTherapeutics announces oral presentation duringClinical trialRecurrent high gradeChief scientific officerFast track designationPaul peter tak

Candel Therapeutics Announces Oral Presentation During The 5Th Glioblastoma Drug Development Summit With Update On Phase 1B Clinical Trial Of CAN-3110

Candel Therapeutics Announces Oral Presentation During The 5Th Glioblastoma Drug Development Summit With Update On Phase 1B Clinical Trial Of CAN-3110
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesAljanae reynoldsTheodore jenkinsFrancesca baroneGlioblastoma drug development summitDrug administrationExchange commissionCandel therapeutics incBusiness developmentCompany nasdaqChief scientific officerFast track designationPaul peter takInvestigational new drug enablingPrivate securities litigation reform actAnnual report

Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC

The first experimental agent from the enLIGHTEN™ Discovery Platform is Alpha-201-macro1, an investigational viral immunotherapy designed to activate innate immune surveillanceApplication of the.

San diegoUnited statesSylvia wheelerAljanae reynoldsFrancesca baronePennsylvania centerSociety for immunotherapy of cancerGlobenewswire incCandel therapeutics incCompany or candel nasdaqDiscovery platformAdvanced analyticsAnnual meetingPeter takChief executive officerChief scientific officer